COVID-19 & Respiratory Virus Public Health Updates Winter 2023

Dr. Jessica de Jarnette


Covid-19 Therapeutics Task Force Lead

California Dept of Public Health



Statewide Wastewater Surveillance Overview for COVID-19, Influenza, and RSV

COVID-19 Summary: Wastewater concentrations are high in all regions of California and increasing in most regions (ABAHO, Greater Sacramento, San Joaquin Valley, and Souther California). In RANCHO, concentrations are high but currently plateaued.




Influenza A Summary: Concentrations are increasing in Greater Sacramento, San Joaquin Valley, and RANCHO but have recently begun decreasing in ABAHO and Southern CA.

Influenza B Summary: Concentrations are low but detectable in about 48% of sites sampling. The number of sites with Influenza B detections is increasing.


RSV Summary: Concentrations are high in all regions. Concentrations are continuing to increase in Greater Sacramento, San Joaquin Valley, and RANCHO, but are decreasing in ABAHO and plateauing in Southern CA.



Influenza and COVID-19 test positivity increasing; RSV remains elevated.



Source: SARS-CoV-2 ELR Reporting Percentage of Outpatient Visits for Influenza-like Illness (ILI), Percentage of Specimens Testing Positive for SARS-CoV-2 and Other Respiratory Viruses




*Week ending date corresponds to specimen collection or specimen result date for respiratory viruses and outpatient visit date for ILI data. ILI data from sentinel providers; Respiratory virus data, including SARS-CoV-2, from clinical sentinel laboratories. Data are provisional and subject to change.

Laboratory Data Source: Sentinel Clinical Laboratories




Therapeutics Utilization in Skilled Nursing Facility Residents in California 1/2022-11/2023





Biphasic nature of COVID-19: viral \rightarrow inflammatory stage




and WIDE SPECTRUM of severity and clinical manifestations

Asymptomatic/mild disease – loss of smell/taste – Long COVID – pneumonia/resp failure – MIS-C/MIS-A – thromboembolic - Death

- Because of bi-phasic nature, therapies must be appropriately tailored to disease phase:
 - Anti-viral agents are most effective when used EARLY
 - Anti-inflammatory agents are most effective when used LATER



COVID-19 Risk Continuum (age, immune status, co-morbidity, vax)



Sociodemographic factors and non-pharmaceutical interventions affect exposure risk

Original illustration by Dr. William Werbel. Adapted for the





Age is the most important risk factor for severe disease

In the United States, 81% of deaths occurred in those > age 65 •

40-49

1x

2x

10x

years old

50-64

1x

Зx

25x

years old

65-74

1x

5x

60x

years old

1x

8x

Risk of hospitalization/death starts to increase > age 50

30-39

1x

2x

4x

years old

(18% of deaths in 50-64 yr old group)

18-29

group

group

group

years old

Reference

Reference

Reference

Case Fatality rate by age: ullet

ullet

Rate compared

to 18-29 years

Hospitalization³

old¹

Cases²

Death⁴

- ≥85 years 10-27%
- 3-11% 65-84 years

5-17

1x

<1x

<1x

vears old

- 55-64 years 1-3%
- <55 years <1%


0-4


1x

1x

<1x


years old





Kompaniyets L, et al. PrevChronic Dis 2021;8:E66 https://covid.cdc.gov/covid-data-tracker/#demographics https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-age.html Age is the most important risk factor for severe disease

COVID-19 Death Risk Ratio for Select Age Groups and Underlying Medical Conditions




Center for Infectious Disease:

https://covid.cdc.gov/covid-data-tracker/#demographics https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-age.html

Kompaniyets L, et al. PrevChronic Dis 2021;8:E66

Summary of COVID-19 Preventative Agents and Treatments





Sunsetting U.S. Government COVID-19 Therapeutics Distribution Program

Projected Timeline (All subject to change)	Action/Event	Product
10/2/2023	HHS switched Lagevrio threshold/replenishment to an out-of-cycle (OOC) process.	Lagevrio
11/1/2023	Commercial Lagevrio launch by Merck (unique NDC relative to USG-procured supply). Lagevrio available for purchase.	Lagevrio
11/1/2023	Commercial Paxlovid launch by Pfizer (NDA-labeled, unique NDC relative to Emergency Use Authorization (EUA)-labeled, USG-procured supply. Paxlovid available for purchase.	Paxlovid (standard and renal dose packaging)
11/10/2023, 12:00PM PT	Last day for awardees to submit orders for Lagevrio USG product (certain federal entities can continue to order USG supply).	Lagevrio
11/27/2023	HHS switch from the Paxlovid threshold/replenishment to an OOC request process.	Paxlovid (standard and renal dose packaging)
12/15/2023, 12:00PM PT	Last day for awardees to submit orders for Paxlovid USG product (certain federal entities can continue to order USG supply.)	Paxlovid (standard and renal dose packaging)
12/15/2023	Ordering pause for Lagevrio for HRSA, DoS, IHS, PC, BOP, ICE, and NIH to determine thresholds based on remaining USG inventory.	Lagevrio
11/15/2023 - 12/31/2023	Providers with excess USG-distributed, EUA-labeled Paxlovid are encouraged to return product through the Pfizer returns process to facilitate a credit to USG.	Paxlovid (standard and reduced dose packaging)

Sunsetting U.S. Government COVID-19 Therapeutics Distribution Program HHS COVID-19 Transition to Commercial Distribution FAQs



New California Health Alert



TOMÁS J. ARAGÓN, M.D., Dr.P.H. State Public Health Officer & Director State of California—Health and Human Services Agency California Department of Public Health



GAVIN NEWSOM Governor

Health Advisory

TO: Healthcare Providers Update on COVID-19 Medications and Transition to Commercial Marketplace 12/18/2023

Update on COVID-19 Medications and Transition to Commercial Marketplace




Programs for Uninsured and Underinsured Individuals

Product	Programs	Description and Additional Information
Lagevrio	Patient Assistance Program	<u>Merck Programs - Lagevrio (merckhelps.com)</u> Tel: <u>800-727-5400</u>
	Bulk Replacement Program	Tel: <u>888-727-8180</u> Website: <u>Merck Programs - Lagevrio (merckhelps.com)</u>
Paxlovid	Available Now	PAXCESS™ PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets)
	Co-Pay Savings Program	Co-Pay Savings Program will be available for eligible
Paxlovid	Available Now	PAXCESS™ PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets)
	Patient Assistance Program using USG supply	Website: PAXCESS™ PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets) Tel: 1-877-219-7225 (1-877-C19-PACK) Through December 31, 2024: Anyone uninsured or covered by federal programs, such as Medicare or Medicaid, can receive USG-procured, NDA-labeled Paxlovid at no cost through the USG PAP operated by Pfizer. Through this program, participating PAP dispensing sites will be reimbursed for any product dispensed, along with a dispensing fee. For retail pharmacies that would like to learn more about participating in the U.S. Government PAP, please contact the program vendor at PharmacyNetworkContract102101@assistrx.com. Starting January 1, 2025: Eligible uninsured and underinsured patients can receive USG procured, NDA-labeled Paxlovid at no cost. Through this program, participating PAP dispensing sites will be reimbursed for any product dispensed, along with a dispensed, along with a dispensed patients can receive USG procured, NDA-labeled Paxlovid at no cost. Through this program, participating PAP dispensing sites will be reimbursed for any product dispensed, along with a dispensing fee.

Overview: PAXCESS Patient Assistance Program (PAP)

Supporting Patients Prescribed PAXLOVID through 2 Distinct Offerings



*Eligible commercially insured patients can save up to \$1,500 per prescription. Maximum annual savings up to \$1,500. Terms and conditions apply. Please visit <u>www.PAXLOVID.com/paxcess-terms-and-conditions</u> for full terms and conditions.

*USG PAP eligibility also includes patients insured through TRICARE and the VA Community Care Network


© 2023 Pfizer Inc. All rights reserved. PP-C1D-USA-0244 November 2023

Please see full Prescribing Information including BOXED WARNING at this presentation or at <u>www.paxlovid.pfizerpro.com</u> Poxlovid [nirmatrelvir 1828] ritonavir 1828]



PAXCESS™ | PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets)

Retail Pharmacy Participating in U.S.G. PAP




PAXCESS[™] | PAXLOVID[™] (nirmatrelvir tablets; ritonavir tablets)

PharmacyNetworkContract102101@assistrx.com




Long-term Care Pharmacy Participating in U.S.G. PAP





Overnight Ship: Maintaining Access to Product



End-to-end process time: ~24 hours*

*Exceptions include but may not be limited to: 3 PM ET cutoff for overnight orders; delivery and order processing not available on Sunday



COVID-19 Medical Coverage Changes


Following End of Federal Public Health Emergency (PHE)

	Vaccines	Treatment	Testing			
Medi-Cal Fee-for- Service	Free COVID-19 vaccines. ¹	Free COVID-19 treatment and related doctor visits is guaranteed at least until September 30, 2024. ²	Free COVID-19 testing if ordered by a doctor. Eight free at-home test kits per month are guaranteed at least until September 30, 2024. ²			
Medi-Cal Managed Care	Free COVID-19 vaccines. ³	Free COVID-19 treatment and related doctor appointments. ³	Free COVID-19 testing, including eight free at-home test kits per month.			
Medicare	Free COVID-19 vaccines with in- network providers.⁴	Free COVID-19 oral medications. COVID-19 hospital visits and doctor visits with in-network providers are covered, but cost-sharing varies by plan. ⁵	Free COVID-19 testing if ordered by a doctor. The cost of athome test kits for people with Medicare Advantage will vary by plan and might be free in some plans.			
			Some Medicare Advantage plans may still provide free at- home COVID-19 tests. ⁴			
			Medicare – Dual coverage also known as Medi-Medi where Medicare does not provide coverage for over-the-counter (OTC) COVID tests, Medi-Cal will provide coverage for the OTC COVID antigen tests through the Medi-Cal Rx benefit.			
California Regulated	Free COVID-19 vaccines, treatment, and testing with in-network providers, ³ including eight at-home test kits per month via SB510.					
Private Plans	Using out-of-network providers may result in costs such as co-pays.					
Uninsured	Until December 31, 2024 through the Bridge Access Program (BAP) ⁶ : Low-cost or free COVID-19 health care provider visits at FQHCs and free clinics. Free COVID-19 vaccines at BAP pharmacies, community organizations, clinics and FQHCs. See more resources at the <u>CDC Bridge Access program</u> and <u>Vaccines for Children</u> . ⁵ COVID-19 oral antivirals (OAV) will remain no cost until the government procured product is depleted. Once government procured product is no longer available, uninsured patients will have access to free OAV through the manufacturer's patient assistance programs. Learn more: <u>testinglocator.cdc.gov</u> . ⁷					



SMARTER Steps Protective Layers

No single intervention or "step" is perfect at preventing the spread of respiratory viruses, like flu, COVID-19 and RSV. However, the more "SMARTER Steps" you take, the safer you, your family, and your community are, especially if you or someone you live with is at higher risk for serious disease.





Awareness Campaign Resumed!

Radio, social media, and digital media to increase public awareness of COVID-19 treatments resumed on November 13, 2023.

Running in English and Spanish until January 15, 2024

Targeted to older than 50 population








Helpful Messaging Practices

- "COVID-19 Medications" or "COVID-19 Prescription Medications" rather than "COVID-19 Treatments"
- Free?: While government-purchased supplies last, the medications are free whether or not you have insurance or citizenship status
- Emphasize: Must be started within the first 5 days of symptoms (don't wait until symptoms get worse!)
- **Remind:** Recommended for most adults (and some teens). Many don't know that they have eligible factors.
- Clarify: For both vaccinated and unvaccinated



Toolkit: Handouts, Graphics, Videos, Wallet Cards





COVID-19 Treatments Communication Tools for the Public

Toolkit for Providers Readiness Checklists, Best Practices Toolkits, and More



March 2023 • # 2023, California Department of Public Health **CDVID-03 Surge Readment: Long Term Care Facilities** Outreach to providers caring for your residents: 3 Converge Fact to review (OPA OR Mithelity MyNory, Resider to Low Review to Press Its COVID-19 Surge Readiness

Best Practices for Skilled Nursing Facilities

Saving lives and avoiding hespitalizations

Even are being seven land heighted and an anti-feed with tready CORD. It results with the value and effective, even with thinging rankets. Insummers carvisep residents, clients and staff hars developing seven disease and map help them test negative for \$2000 (Husanes, Preparing before a positive \$25/0-18 -case property will help residents and staff get treated fashes.

This calls mentions predicters that 300 long term care restlering are considered all lighter risk for severe (2010) It and the decisive in not answrite (2010) of insufacest developer expressible disations in which the data of presenting characterized in the present to all transmission presenting baseling they be and the potential for reduced risk of long ODME:

The California Department of Public Healthy (CDPH) CORED 22 (Therapeutics Task Force wants to support you in getting waip for potential COND Divarges is pair finally CDM anderstands that facilities do not cardral the actions and decision of individual health care providers. However, you can help facilitate treatments for your residents and staff with proparachess acharation, and perting the light place into place. The CBPH CONC. 31 Theraposities Task Portoch-analiable its assist you will closeloping heat practices and estaration for your situation. Not call contact to at COVERation/departments applied in the call RED SIG-EDS from Results' to Weider Results (gen. Viscour also are the Provider CDVID-D) Coll Control result on the effected collection and the

Surge preparedness tips: baseline strategies

- Encourage nearing starts with good hi and Woodcon Barrenia, Webla and Kilow.
- Isolating and cohorting Ripatanto.
- · Testing staff and headlershy with comptoms:
- Perparing for increasing use of CDHD 31 lends on do.
- 1. Beach out to your residents' beach care providers.
- 2. Confirm supply with your pharmacy, Apacobia
- 3. Sevelop a pipe.
- 4. Bitaniate year defi-
- tailors resident; evident exercisitation of treatment symbolizing



Even if your symptoms are mild, treating COVID-19 guickly can help prevent you from getting severely ill. GET COVID-19 TREATMENT!

COVID-19 treatment is safe, and effective-and most adults are eligible to receive it.



IF YOU HAVE A POSITIVE TEST AND ANY SYMPTOMS:

days of symptoms.

what to do if

Call your health care provider right away, or ...

Updated flyer

for LTCF staff!

If you don't have a regular health care provider or cannot see them in 24 hours, as a long term care facility worker, you can access a FREE appointment with a health care provider by calling Sesame Care at (833) 686-5051 or visiting sesamecare.com/covidca to be evaluated for treatment, or...

Visit testtotreat.org to sign up for the National Home Test to Treat Program, which offers free COVID-19 telehealth care in addition to at-home tests. Free home delivery of medications is also available through this program but act fast as COVID-19 medications must be taken within the first 5

DON'T DELAY ... You must start taking COVID-19 medications as soon as possible after your symptoms appear.



You can help save lives by helping your residents get access to COVID-19 medications too! Refer positive residents with symptoms to a health care provider!

California Department of Public Health | COVID-19 Therapeutics CTX-1009(11/23-13)





COVID-19 Treatments Resources for Healthcare Providers

COVIDRxProviders@cdph.ca.gov



Respiratory Virus Prevention Communications Tools



Don't Let COVID-19 and Flu get you: College Student Edition



"6 Tips for Staying Healthy this Virus Season" Handout



Consider judging a much in public indicer or created spaces expectedly if you or your benity is.

Back your bands often, with youp and warm water, for at least 20 seconds. It support water are

Cough in steeperints your efforte, ann, or a disposable titles. Hale sure to want your hands or

Suptamber 2023 - 0 2021. California Separtment of Public South

4 higher dat he seven illere Waah Your Hands

Cover Your Caugh or Stream

samilian and depend of your lives after.

not available, use a hand can itser with at least 52% alcohol.

ican the (3) so is to see

eternetive links are this flyer

Social Media





Respiratory Virus Prevention Communications Toolkit

Webinar: Respiratory Viruses in Older Californians



When: Wednesdays, January 10 & 24th, 2024

Time: 12-1PM, PT

To create a profile and register:

Project ECHO Respiratory Viruses in Older Californians Webinar Series



COVID-19 Therapeutics Resources



Type of Support		Description	Updated 11.27.23
	Clinical Guidance	For general Therapeutics questions, please email: <u>COVIDRxProviders@cdph.ca.gov</u> COVID-19 Treatment Warmline for SNF and LTCF staff: 1.866.268.4322 M-F 8am-5pm	
			<u>/ebpage</u> (provides general information for healthcare providers, allocations, Irug facts sheets, and additional resources)
	General Information	CDPH COVID-19 Treatments J	ob Aid (questions and answers for the public on COVID-19 therapeutics)
		COVID-19 Therapeutics Best F	ractices Checklist (testing, prescribing, dispensing, and more)
		Frequently Asked Questions do	cument for clinics, providers, and pharmacists
	Locating Resources	Finding Providers and Test-to-T	reat Sites
		 <u>COVID-19 Therapeutics Lo</u> 	<u>cator</u> (arcgis.com)
		 <u>Test-to-Treat</u> (hhs.gov) 	
	<u>LHJ Therapeutics</u> <u>SharePoint</u>	Primary source for recorded web <u>JEOCuser54@cdph.ca.gov</u>)	inars, slides, datasets and HPOP reporting information. (For access, email
		 <u>Therapeutic Weekly Email</u> 	<u>Update</u> files (SharePoint)
		<u>CDPH Therapeutics HPoP</u>	Account Verification & Reporting information
Ê	Questions		s questions, please email <u>COVIDRxProviders@cdph.ca.gov</u> signing up new HPOP Accounts: please e-mail <u>CDPHTherapeutics@cdph.ca.gov</u>

COVID-19 Therapeutics Provider Warmline

The California COVID-19 Therapeutics Provider Warmline is available for healthcare professionals in California-based long-term care and skilled nursing facilities until June 30, 2024!



The National Clinician Consultation Center offers free and confidential consultation on COVID-19 testing and treatment. Healthcare professionals in California working in a long-term care or skilled nursing facility of any experience level can speak with our clinician or pharmacist.

No Protected Health Information (PHI) will be collected -- only basic provider contact and facility information.

Call 1-866-268-4322 (1-866-COVID-CA) or submit an <u>online request form</u>. Hours: Monday through Friday, 9AM – 5PM. All voicemail messages will be returned on the next business day.



Any Questions?

Thank you and Happy Holidays!

